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INTRODUCTION
Over the past decade, several experimental and clinical studies 
reported on the successful use of adeno-associated virus (AAV)-
based vectors (particularly AAV9) for central nervous system (CNS)-
targeted gene delivery. These studies established unequivocally the 
value of AAV-based-delivery vectors as a tool to achieve a potent 
gene silencing or upregulation in targeted CNS regions and provided 
evidence that this therapeutic approach can effectively be used in 
treatment of numerous neurological disorders, including ALS, SMA, 
muscle spasticity, and chronic pain. Despite these encouraging data 
and extensive preclinical animal studies, detailed mechanisms on 
how the AAV vectors penetrate into the brain or spinal cord paren-
chyma after using different routes of AAV delivery (e.g., systemic, 
intrathecal) are not fully understood. These data are critical for the 
development of new and more effective AAV delivery protocols that 
would be equally potent in young and in fully developed adult ani-
mals and in human patients. In general, preclinical animal studies 
can be categorized into several groups based on the developmental 
stage when the animal is employed or the route by which the AAV 
is delivered (systemic or intrathecal). Depending on the parameters 
used in the individual studies, the level of transgene expression and 
the specific cell populations (neuronal and/or glial) that are being 
infected vary greatly.
First, early studies have demonstrated that systemic-vein (i.v.) 
injection of AAV9-GFP in neonatal mice leads to widespread CNS 
green fluorescent protein (GFP) expression, including dorsal root 
ganglia, spinal motoneurons (MN), and neurons in the brain (neo-
cortex, hippocampus, cerebellum). Using adult mice, i.v.-delivered 
AAV9-GFP leads to a preferential astrocyte infection through-
out the entire CNS, but only limited neuronal expression is seen.1 
Comparable data were reported by Barkats et al.2 who demon-
strated widespread spinal MN GFP expression after systemic i.v. 
delivery of AAV9 in neonatal mice. In addition, the same group dem-
onstrated successful transgene expression in spinal MN once AAV9 
was delivered i.v. in adult mice or cats.2 Similar to these two studies, 
Gray et al. have shown CNS neuronal GFP expression after i.v. AAV9 
administration in adult mice, however, only limited transduction 
efficiency was seen in juvenile non-human primates; compared to 
a previous study performed by Foust and Kaspar et al.,1 a clear shift 
from neuronal to glial expression was seen in the brain.3
Second, given the apparent limited neuronal expression after sys-
temic i.v. AAV9 delivery in adult animals, use of the intrathecal route 
(to bypass the blood-brain barrier) was explored in several stud-
ies. Using 1-year-old, 2 kg BW, non-human primates (Cynomolgus 
macaques), it was demonstrated that a single lumbar-intrathecal 
injection of AAV9-CB-GFP led to 50–75% MN transduction in the 
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Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in 
adult rats and pigs
A Miyanohara et al.
Effective in vivo use of adeno-associated virus (AAV)-based vectors to achieve gene-specific silencing or upregulation in the central 
nervous system has been limited by the inability to provide more than limited deep parenchymal expression in adult animals using 
delivery routes with the most clinical relevance (intravenous or intrathecal). Here, we demonstrate that the spinal pia membrane 
represents the primary barrier limiting effective AAV9 penetration into the spinal parenchyma after intrathecal AAV9 delivery. We 
develop a novel subpial AAV9 delivery technique and AAV9-dextran formulation. We use these in adult rats and pigs to show (i) 
potent spinal parenchymal transgene expression in white and gray matter including neurons, glial and endothelial cells after single 
bolus subpial AAV9 delivery; (ii) delivery to almost all apparent descending motor axons throughout the length of the spinal cord 
after cervical or thoracic subpial AAV9 injection; (iii) potent retrograde transgene expression in brain motor centers (motor cortex 
and brain stem); and (iv) the relative safety of this approach by defining normal neurological function for up to 6 months after AAV9 
delivery. Thus, subpial delivery of AAV9 enables gene-based therapies with a wide range of potential experimental and clinical 
utilizations in adult animals and human patients.
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entire spinal cord at 2 weeks after AAV9 injection.4,5 Similarly, in 
another study using juvenile 2- to 3-year-old nonhuman primates 
(Cynomolgus macaques) or young (2-month-old) pigs, potent 
MN transduction was seen throughout the entire spinal cord after 
intra-cisternal or combined cisternal-lumbar intrathecal AAV9 deliv-
ery. In addition, in the same study, GFP expression was observed 
in dorsal root ganglion cells, motor cortex and in Purkinje cells in 
the cerebellar cortex.6 In a more recent study, comparable lumbar 
MN GFP expression was seen in nonhuman primates (Cynomolgus 
macaques) after intra-cisternal AAV9-GFP injection.7
Interestingly, in all studies that employ a cisternal or lumbo-sacral 
intrathecal delivery route, the available histological data show a very 
specific spinal transgene expression pattern. It is characterized by 
intense expression in α-motoneurons. However, the ventral horn 
interneurons, which reside in close proximity to the GFP-expressing 
α-motoneurons, appear to be transgene negative. Similarly, potent 
transgene expression is seen in dorsal root ganglion cells and primary 
afferents. However, small interneurons localized in the superficial dor-
sal horn or in the intermediate zone show no transgene expression.
This high level of transgene expression selectivity and lack of 
transduction in deeper gray matter cells indicates the presence of 
a well-developed regulatory-barrier system (in addition to blood–
brain barrier) that prevents the penetration of virus into deeper 
spinal compartments from the intrathecal space. Based on the well-
described anatomical organization of spinal meninges, we hypoth-
esized that the pia mater represents the key barrier that regulates 
the penetration of AAV into the spinal parenchyma after intrathe-
cal AAV delivery. We also speculate that the high level of transgene 
expression seen in MN and DRG cells reported after IT delivery is 
likely mediated by the preferential retro- and antero-grade infec-
tion of axons projecting into and out of the spinal parenchyma and 
trans-passing the IT space (i.e., ventral and dorsal roots).
Accordingly, to address this issue, we have developed and vali-
dated a subpial (SP) vector delivery method in adult rats and pigs 
and provide evidence that this delivery route leads to potent trans-
spinal transgene expression infecting the entire population of neu-
rons in the gray matter of subpially-injected segments. In addition, 
near complete infection of descending and ascending axons was 
achieved and corresponded with the transgene expression in brain 
centers (motor cortex, nucleus ruber). Overall, this study provides 
one of the first evaluations of the mechanism by which AAV9 vec-
tors target cells throughout the CNS.
ReSUlTS
Effective spinal parenchymal AAV9-mediated transgene expression 
after single bolus subpial AAV9-UBI-GFP (or -RFP) injection in adult 
rats and pigs
We first tested the potency of single bolus subpial AAV9-UBI-
GFP or AAV9-UBI-RFP delivery in rats and pigs (Figures  1 and 2; 
Supplementary Figure  S1). Animals received 30 μl (rats) or 200 μl 
(pigs) of AAV9 vector in 2.5% dextran solution delivered into the sub-
pial space of cervical (C4-6), thoracic (Th6-9) or lumbar (L2-L5) seg-
ments. At 8 weeks after AAV9 delivery, spinal cords were dissected 
from 4% paraformaldehyde perfusion-fixed animals and imaged in 
situ using an Avis fluorescence system. Transverse or horizontal spi-
nal cord sections were then cut from AAV9-injected segments and 
analyzed for the presence of GFP or red fluorescent protein (RFP) 
and costained with neuronal (NeuN), glial (glial fibrillary acidic pro-
tein (GFAP), CC1) and endothelial (RECA-1) antibodies. No anti-GFP 
or anti-RFP antibodies were used in any of the staining combinations 
presented and the captured GFP and RFP signals represent a “true” 
transgene expression. In both rat and pig spinal cords, an intense GFP 
or RFP expression was seen on the surface of the spinal cord and was 
readily identified by visual inspection as yellow-green or red areas. 
Figure 1h,j shows the presence of RFP (red color) in transversely cut 
pig spinal cord and in the ventral roots (H-insert) in comparison to 
naive spinal cord (i). Correspondingly, the spinal surface densitomet-
ric analysis of AAV9-UBI-GFP-injected animals (rats and pigs) showed 
a widespread GFP signal extending for up to 5–10 cm from the epi-
center of the subpial AAV9 delivery (Figure 1f,g).
Using horizontally cut spinal thoracic sections taken from pigs pre-
viously injected SP with AAV9-UBI-RFP in the mid-thoracic level (the 
same spinal cord as shown in Figure 1h), extensive parenchymal RFP 
expression was seen. The RFP expression was readily identified in the 
majority of interneurons and α-motoneurons and extended through-
out four to six spinal segments (Figure  2a,b). Similarly, intense RFP 
expression in the axo-dendritic arbor was seen throughout the whole 
RFP-expressing gray matter (Figure 2a,b—white asterisks).
Analysis of transverse spinal cord sections taken from the 
epicenter of SP AAV9 injection confirmed intense RFP expres-
sion throughout the white and gray matter. In the white mat-
ter, a punctate-like RFP expression was seen in the majority of 
transversally-cut axons (Figure 2c—white asterisks—yellow box 
inserts) and were identified in dorsal, lateral and ventral funiculi 
(Figure  2c—DF, LF, VF; yellow box inserts). In the gray matter, 
numerous interneurons distributed between laminae I-IX and 
ventral α-motoneurons showed intense RFP expression in soma 
and in axo-dendritic arbor. A high density of RFP expression 
was also seen in the terminal boutons throughout the gray mat-
ter (Figure  2d–g). Similarly, confocal analysis showed the pres-
ence of RFP signal in astrocytes (Figure  2c—insert: RFP/GFAP). 
In transverse spinal cord sections taken from naive pigs stained 
with NeuN antibody and developed with FITC secondary anti-
body, no background RFP signal was detected once images were 
captured with both 488 and 594 filters (Figure 2h).
A similar neuronal GFP expression pattern was seen in the rat 
lumbar spinal cord after SP AAV9-UBI-GFP injection at the L1-2 level. 
A high density of GFP+ neurons throughout the L1-L5 lumbar seg-
ments localized in the whole gray matter between laminae I-IX were 
identified (Supplementary Figure S1a).
A quantitative segmental analysis of GFP expressing neurons 
(α-motoneurons and interneurons) in rats (n = 3) and pigs (n = 3) receiv-
ing upper lumbar (L1-2) subpial AAV9-UBI-GFP injection and surviving 
for 6 months is shown in Table 2. In general, a consistent high-level neu-
ronal transgene expression was seen in five to seven segments above 
and below the site of AAV9 injection. No neuronal transgene expres-
sion was seen in cervical neurons after lumbar subpial AAV9 delivery or 
in lumbar neurons after cervical subpial AAV9 delivery.
Descending motor axon GFP expression in spinal segments distant 
from the site of subpial AAV9-UBI-GFP delivery
We next characterized the extent of descending spinal tract GFP 
expression in the lumbar spinal cord after SP injection of AAV9- 
UBI-GFP into the subpial space of the mid-thoracic (Th6-7) or lower 
cervical segments in both rats and pigs. At 3–6 weeks after SP AAV9 
delivery, intense GFP expression was seen throughout the whole lum-
bar spinal cord. Using transverse lumbar (L2-L6) spinal cord sections 
taken from pigs, high-intensity GFP expression in transversely-cut 
axons in the lateral and ventral funiculi was readily identified without 
additional GFP immunostaining (Figure 3a; white asterisks). In these 
regions, a similar density of GFP+ axons was seen throughout the 
whole white matter. In comparison to lateral and ventral funiculi, a 
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relatively lower number of GFP+ axons was seen in the dorsal funiculi 
(Figure 3a; DF). Consistent with the degree of axonal labeling seen 
in the white matter of lateral and ventral funiculi, a dense network 
of GFP+ axons terminating in the gray matter was seen (Figure 3a,b). 
These axons were identified between laminae III-X. Only a few GFP+ 
axons in the lamina I-III were seen. High-power confocal microscopy 
showed a high density of fine GFP+ axons with numerous terminal 
boutons in the gray matter (Figure 3c).
A comparable GFP expression pattern in descending motor axons 
in the lumbar gray matter was seen in rats previously receiving upper 
cervical SP injection of AAV9-UBI-GFP (Supplementary Figure S1b).
Effective retrograde transgene expression in brain motor regions 
after spinal subpial AAV9-UBI-GFP delivery in rats and pigs
Analysis of transgene (GFP) expression in brain motor centers (motor 
cortex, nucleus ruber, and formatio reticularis) at 6 weeks after SP 
Figure 1  Technique of subpial AAV9 delivery and macroscopically defined spinal cord surface transgene expression. (a) Schematic drawing of spinal 
cord, meninges and sub-pially placed PE-10 catheter in pigs. (b) A catheter guiding tube (18G) is used to advance the PE-10 catheter into the subpial 
space. (c–e) To place the catheter into the subpial space, the dura mater is first cut open (c) and the catheter is advanced into the SP space (d,e). An air 
bubble injected into the subpial space can be seen (d-asterisk). (f,g) Surface GFP fluorescence densitometry shows an intense signal in both rat and pig 
spinal cord with the most intense GFP fluorescence seen at the epicenter of lumbar subpial injection. (h–j) The presence of intense RFP fluorescence in 
the spinal cord parenchyma detected macroscopically in pig thoracic spinal cord (h,j). A clear high level of RFP expression in ventral roots can also be 
seen (h-insert). No fluorescence in the control noninjected spinal cord can be identified (i).
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AAV9-UBI-GFP delivery (n = 2) in pigs showed intense GFP-labeled 
pyramidal neurons in the motor cortex (Figure  4a–e). Similarly, 
numerous GFP+ neurons localized in the brain stem were identi-
fied (Figure 4f–j). Consistent with the presence of GFP+ neurons in 
the motor cortex, a high number of GFP+ corticospinal axons in the 
ventral region of the medulla oblongata (medullary pyramids) was 
seen (Figure 4k). In addition, a high density of anterogradely labeled 
GFP+ spinoreticular terminals was seen throughout the reticular 
formation (Figure  4l), as well as in spinothalamic terminals in the 
thalamic nuclei (not shown).
Comparably as seen in pigs, using sagittal sections taken from the 
medulla oblongata and cerebellum in rats, a high density of GFP+ 
fiber network was identified at 8 weeks after cervical subpial AAV9-
UBI-GFP injection (Figure 5a–c). In addition, clearly labeled spino-
cerebellar tract fibers in the cerebellum were seen (Figure 5a; insert).
Using coronal sections taken from the brain stem and motor 
cortex, intense labeling of nucleus ruber neurons (NR), ascending 
spinothalamic fibers in the medial lemniscus (ML) and descending 
corticospinal tract (CPD; cerebral peduncle) was consistently seen 
(Figure 6a). Corresponding to the intense corticospinal tract labeling 
seen at the level of the brain stem and medulla oblongata, clear GFP 
expression in cortical neurons in layer V was seen. No GFP expression 
in other cortical layers was identified (Figure 6b; insert No. 3).
Differential regional spinal transgene expression after intrathecal 
versus subpial AAV9 delivery
We next compared the distribution of spinal transgene expression 
after the AAV9-UBI-GFP was injected into the lumbar intrathecal 
(N = 5) or lumbar subpial (L1-L2; N = 4) space (Figure 7a–f). After 
AAV9 delivery, animals survived for 3 months.
IT injection of AAV9-UBI-GFP led to intense GFP expression in 
the dorsal funiculus, primary afferents in the dorsal horn (lam-
ina II-III) and in the medial part of lamina V-VII. Several GFP+ Ia 
afferents terminating in the ventral horn in the vicinity of large 
α-motoneurons were also identified (Figure  7a; lower right 
insert). Consistent with high GFP expression in primary affer-
ents, a high number of GFP+ neurons were found in the dorsal 
root ganglion cells (Figure 7a; upper right B/W insert). The clear 
presence of increased GFP expression was also consistently seen 
Figure 2 Effective parenchymal AAV9-mediated transgene expression 
after single bolus subpial AAV9-UBI-RFP injection in adult pigs. (a,b) 
Horizontal spinal cord sections taken from the mid-thoracic spinal cord 
of pigs injected with AAV9-UBI-RGF 6 weeks previously. Intense RFP 
expression can be seen throughout the whole region, including the 
white and gray matter. Staining with NeuN antibody (green) shows that 
virtually all neurons are also RFP positive. (c–g) Transverse spinal cord 
section taken from the SP-injected region shows transversally-cut RFP+ 
axons in the dorsal (DF) lateral (LF) and ventral (VF) funiculus (yellow box 
inserts). RFP expression can also be seen in glial fibrillary acidic protein 
(GFAP)-stained astrocytes (c insert; RFP/GFAP). High density RFP+ 
terminal boutons surrounding RFP-expressing α-motoneuron (d,e) and 
interneurons (f,g) can be seen. (h) Transverse spinal cord section taken 
from the mid-thoracic spinal cord in a naive animal and stained with anti-
NeuN antibody. Image was acquired using 488 and 594 filter and the 
identical settings as used in Figure 2f. No detectable background RFP 
signal can be seen (Scale bars: a–c-500 μm; d, f-30 μm).
a
b
c
d
e
f g h
Figure 3 Potent GFP expression in descending motor axons in lumbar 
spinal cord after mid-thoracic subpial AAV9 injection in adult pigs. (a,b) 
Transverse spinal cord section taken from the lumbar spinal cord after 
subpial AAV9-UBI-GFP injection into the mid-thoracic subpial space 6 
weeks prior. Intense GFP expression in transversal cut axons in lateral 
(LF) and ventral (VF) funiculus can be seen (white asterisks). A relatively 
lower density of GFP+ axons in the dorsal funiculus was identified (DF). 
Correspondingly, a high density of GFP+ motor axons projecting into 
the gray matter localized between the dorsal horn (DH) and ventral horn 
(VH) can also be seen. (c) A higher resolution confocal image shows very 
fine arborization of GFP+ axons and terminal boutons in the central gray 
matter (Scale bars: a-1,000 μm; c- 30 μm). DF, dorsal funiculus; DH, dorsal 
horn; LF-lateral funiculus; VF, ventral funiculus; VH, ventral horn.
a
b c
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around the ventral root entry zone (Figure 7a; left bottom insert). 
Several GFP expressing glial cells were seen in this region. In the 
ventral gray matter, some α-motoneurons showed GFP expres-
sion (Figure 7a; lower right insert). Except for these regions, and 
cell groups that showed GFP expression, almost a complete lack 
of neuronal or glial GFP expression was seen in other deeper 
regions of the gray matter, including the dorsal horn, interme-
diate zone and in the white matter of the lateral and ventral 
funiculi (Figure  7a–c). Interestingly, even the neurons localized 
in the superficial dorsal horn and which reside in close vicinity 
to the intrathecal space (but separated by pia mater) showed a 
complete lack of GFP expression (Figure 7c).
In contrast to the GFP expression pattern seen after intrathecal 
AAV9-UBI-GFP delivery, the GFP expression resulting from lumbar 
subpial AAV9 injection showed a substantially different regional 
expression pattern and was similar to that seen in adult pigs. 
Intense GFP expression was seen in the majority of interneurons 
and α-motoneurons in the SP-injected segment (Figure  7d–f ) 
as well as in segments localized rostral and caudal from the 
site of SP AAV9 injection (Supplementary Figure  S1a; Table  2). 
Corresponding with high α-motoneuronal GFP expression, a con-
sistent GFP signal was seen in ventral root axons (Figure 7d; VR). 
Likewise, a high intensity of GFP expression was seen in virtually 
all axons in the lateral and ventral funiculi (Figure  7d; LF, VF). 
Similarly as seen in pigs, rats that previously received cervical SP 
AAV9 injection, a high density of GFP+ axonal network was seen 
in segments distal to the site of cervical injection in all thoraco-
lumbo-sacral segments (Supplementary Figure S1b).
Expression of GFP in glial and endothelial cells after lumbar subpial 
AAV9-UBI-GFP delivery in rats
We next tested the cellular specificity of GFP expression at 6 months 
after lumbar subpial injection of AAV9-UBI-GFP in rats. Staining 
with anti-GFAP, CC1 and RECA-1 antibodies and confocal analysis 
showed clearly detectable GFP expression in glial and endothelial 
cells (Figure 8a–i).
Long-term+ neurological effect of lumbar subpial AAV9-UBI-GFP 
delivery in rats and pigs
Periodic analysis of motor and sensory (allodynia) function in rats 
(n = 6) showed no detectable deficit for 6 months post-AAV9 deliv-
ery. A transient motor weakness (motor score: 10) was seen in one 
of four pigs between 3–21 days after AAV9-delivery. The same ani-
mal also showed increased vocalization to skin pinch (i.e., allodynia). 
Allodynia and motor weakness were no longer present at intervals 
longer than 30 days after AAV9 injection.
Figure 4 Retrograde infection-mediated GFP expression in brain motor 
centers after subpial mid-thoracic AAV9 delivery in adult pigs. (a–e) 
Retrogradely labeled pyramidal neurons in the motor cortex of pigs 
at 6 weeks after a mid-thoracic single AAV9-UBI-GFP injection. (f–j) 
A comparable level of GFP expression in neurons localized in the brain 
stem can be seen. (k) Presence of large retrogradely-labeled motor GFP+ 
axons in the medulla oblongata (medullary pyramids) can be identified. 
(l) A high density of anterogradely labeled sensory afferents in formatio 
reticularis (Scale bars: a–e and g–j-50 μm; k, l-50 μm).
a
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Figure 5 Retrograde and anterograde-transport-mediated GFP express-
ion in medulla oblongata and cerebellum at 8 weeks after subpial 
cervical AAV9 delivery in adult rats. (a–c) An intense GFP expression 
in medulla oblongata representing a mixture of retrogradely and 
anterogradely labeled axons can be seen. A fine arborization of GFP-
expressing spino-cerebellar tract terminals in the cerebellum can also 
be identified (a; insert) (Scale bar: a-2 mm; insert-200 μm; b, c-500 μm).
a
b c
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DISCUSSION
Surgical-technical and safety considerations of subpial catheter 
placement
To place the SP catheter in adult rats or pigs, several sequential pro-
cedural steps are followed to minimize potential spinal injury asso-
ciated with instruments/catheter manipulation in the vicinity of 
the exposed “dura-free” spinal cord. First, the use of caudal and cra-
nial spinal clamps (placed just above and below the laminectomy) 
proved to be essential in minimizing spinal cord pulsation during 
catheter placement. Second, an “L” shaped catheter-guiding stain-
less steel tube mounted on an XYZ manipulator is used for SP cath-
eter placement. The pia is first punctured using a bent 30G needle. 
Once the tip of the penetrating 30G needle is in the subpial space 
for about 1–1.5 mm, the pia is slightly lifted for 1–2 mm. A PE-10 
catheter (pigs) is then placed into the SP space by advancing the 
catheter from the guiding tube. After the catheter is advanced to 
the targeted length, the penetrating needle is removed from the SP 
space. Once the vector injection is completed (typically over 3 min-
utes), the catheter is slowly pulled out of the SP space and the dura 
is closed. By using this technical approach, the placement of the SP 
catheter takes an average of 3–5 minutes from the moment of dura 
opening. Currently, we have placed the SP catheter in over 25 pigs 
using this technique and achieved consistent and injury-free SP 
catheter placement. In our early attempts, we tried the SP catheter 
placement by free hand (without the use of a guiding tube and XYZ 
manipulator). These attempts were unsuccessful and resulted in 
local spinal cord injury and bleeding and/or inconsistent placement 
of the catheter in the SP space with some catheters penetrating the 
superficial layers of the spinal cord tissue. An identical technique is 
used in adult rats, however, a PE-5 catheter is used instead.
Subpial AAV9 delivery leads to widespread transgene expression 
in neurons throughout the gray matter and ascending and 
descending axons in SP-injected segments
As we have shown in our present study, a single subpial AAV9 
injection led to potent parenchymal transgene expression spread-
ing rostro-caudally for multiple segments. In adult pig spinal cord, 
Figure 6 Retrograde and anterograde-transport-mediated GFP 
expression in the brain stem and motor cortex at 8 weeks after subpial 
cervical AAV9 delivery in adult rats. (a) Intense bilateral GFP expression 
can be seen throughout the brain stem (NR, nucleus ruber; ML, medial 
lemniscus; CPD, cerebral peduncle). (b) Specific and intense GFP 
expression in retrogradely-labeled pyramidal neurons in the motor 
cortex (layer V) can be identified (MOp-primary somatomotor area; 
CC-corpus callosum; ACB-nucleus accumbens) (Scale bars: a-1 mm; 
inserts No.1 and No.2–50 μm; b-1mm; inserts No.1–250 μm; No.1-1-50 
μm; No.2 and No.3–250 μm).
a
b
Figure 7 Differential regional spinal transgene expression after 
intrathecal AAV9-UBI-GFP versus subpial AAV9-UBI-RFP delivery in 
rats. (a–c) Lumbar intrathecal injection of AAV9-UBI-GFP led to the 
preferential GFP expression in the dorsal funiculus (DF), primary afferents 
distributed in the dorsal and ventral gray matter (white arrows) and 
dorsal root ganglion neurons (a; upper-right BW insert). A subpopulation 
of α-motoneurons and glial cells localized in the ventral root entry zone 
(VRE) also show GFP expression (yellow right insert; white left insert-
VRE). No or minimal GFP expression in axons localized in the lateral 
(LF) or ventral funiculi (VF) was seen. Similarly, no GFP expression in 
interneurons in the dorsal horn or in the intermediate zone could be 
detected (b, c). (d–f) In contrast to intrathecal injection, the lumbar 
subpial injection of AAV9-UBI-GFP led to widespread transgene 
expression. Numerous GFP expressing NeuN+ neurons localized 
throughout the gray matter, including interneurons and α-motoneurons, 
were seen (e, f). Consistent with α-motoneuronal GFP expression, high 
GFP expression was seen bilaterally in transversely cut motor axons in 
the ventral roots (d; VR). Similarly, high intensity of GFP was seen virtually 
in all transversely cut axons in the lateral and ventral funiculi (Scale 
bars: a, D-200 μm; b, c, e-50 μm; f-20 μm). CC, central canal; DF, dorsal 
funiculus; DH, dorsal horn; LF, lateral funiculus; VF, ventral funiculus; VH, 
ventral horn; VR, ventral root; VRE, ventral root entry zone.
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the transgene spread was consistently seen at distances rang-
ing between 10–15 cm. Expression was identified in neurons and 
glial cells in all gray matter laminae and in axons in ventral, lateral 
and dorsal funiculi, confirming a near complete penetration of 
SP-injected AAV9 vector throughout the spinal parenchyma. By ana-
lyzing transverse lumbar spinal cord sections in pigs that received 
a mid-thoracic AAV9-UBI-GFP injection (i.e., about 30 cm distance 
from the site of AAV9 delivery), virtually all descending motor 
axons appear to be labeled at 6 weeks after AAV9 injection. Higher-
resolution confocal microscopy revealed a dense network of fine 
axonal arborizations with terminal boutons throughout the gray 
matter. Consistent with the level and distribution of infected axons 
in the white matter, retrogradely infected GFP-expressing neurons 
in the motor cortex and brain stem were identified. Similarly, cen-
trally projecting sensory axons were identified in the reticular for-
mation and in the thalamus. In comparison to rats, the number of 
retrogradely infected cortical or brain stem neurons was relatively 
lower in pigs. Because the analysis of brain GFP expression in pigs 
was done in animals receiving mid-thoracic SP AAV9 injection (and 
not cervical SP AAV9 injection as done in the rats), a relatively lower 
number of labeled cortical/brain stem motor neurons may reflect a 
lower number of descending motor axons that were retrogradely 
infected at the mid thoracic spinal cord.
Pia mater represents a primary barrier for effective parenchymal 
penetration of AAV9 after intrathecal delivery
By comparing the transgene expression pattern after SP versus IT 
AAV9 delivery in rats, we have demonstrated a substantially dif-
ferent regional-cellular expression. First, after intrathecal delivery, 
the expression was only seen in regions and neuronal-glial pools 
that are morphologically associated with the dorsal and ventral 
root entry zone. Thus, potent transgene expression was seen in 
primary afferents and was clearly present in the dorsal funiculi, 
primary afferents in the dorsal horn and Ia afferents projecting to 
the ventral horn. This transgene expression in primary afferents 
corresponded with potent expression in dorsal root ganglion cells. 
Similarly, clear expression was seen around the ventral root entry 
zone with some retrogradely labeled α-motoneurons in the ventral 
horn. In contrast, however, the transgene expression was virtually 
absent in all other neurons between laminae I-VII and X. Moreover, 
no descending motor axons were labeled in the lateral or ventral 
funiculi. These data jointly suggest that the spinal parenchymal GFP 
expression (whether in neurons or projecting primary afferents) is 
almost exclusively caused by retrograde or anterograde transgene 
expression and not by AAV9 uptake into the spinal parenchyma 
from the intrathecal space. This observation is consistent with data 
from other laboratories that demonstrate potent α-motoneuron 
GFP expression after a single intrathecal or cisternal AAV9-GFP 
injection in adult nonhuman primates or juvenile pigs. However, 
no interneuronal GFP expression is seen in interneurons residing in 
close proximity to GFP+ α-motoneurons.4–7
In contrast, as described above, the subpial AAV9 delivery was 
associated with potent transgene expression in the gray matter 
neurons (α-motoneurons and interneurons) and virtually in all 
descending motor axons and primary afferents of injected seg-
ments. These data clearly demonstrate that the pia mater repre-
sents the primary barrier preventing the penetration of AAV9 into 
other spinal cord compartments which are distant from the ventral 
and dorsal root entry zone. By bypassing the pial membrane and 
depositing the AAV9 into the subpial space, a trans-parenchymal 
infection of white and gray matter can be effectively achieved in 
adult rodents or large animals.
Potential clinical and experimental utilization of subpial AAV9 
delivery
The potency of SP-induced infection and the neuronal cell popula-
tions that are being infected in the spinal cord and brain in adult ani-
mals have several potential clinical and experimental implications. 
First, in cases when a specific gene is to be silenced/downregulated 
(such as mutant SOD1 gene in ALS), a single cervical subpial injec-
tion of the silencing AAV9 construct will lead to effective gene silenc-
ing in cervical neurons and glial cells, in descending motor axons 
 throughout the whole length of spinal cord and in the majority of 
ascending sensory fibers. Given well-characterized neurodegen-
erative patterns in amyotrophic lateral sclerosis(ALS) patients and 
experimental models of ALS that display progressive degeneration 
of upper motor neurons, projecting descending motor axons and 
lower motor neurons,8–10 the ability to achieve widespread mutant 
gene silencing will likely provide a substantial advantage in achieving 
the most potent therapeutic effect. In addition, a single cervical SP 
injection can be combined with an additional SP injection into the 
lumbar enlargement to target the lumbar neuronal/glial population 
or with lumbar intrathecal injection to target α-motoneuronal pools 
throughout the thoracic and lumbar spinal cord. Second, increased 
expression of therapeutic genes (e.g., growth factors) associated with 
axonal sprouting can be readily achieved in descending motor tracts 
as well as ascending sensory fibers. For example, this could be tested 
for treatment potency in spinal trauma studies. In the case of the 
AAV9 vector, it can be administered from a single laminectomy site at 
the injury epicenter; the SP catheter could be advanced rostrally and 
caudally to target the distal end of severed motor axons and proximal 
ends of ascending sensory axons, respectively. Third, near complete 
descending motor tract labeling, which can be achieved from cervical 
SP AAV9-GFP injection, will enable studies of axonal sprouting and 
Figure 8 Expression of GFP in glial and endothelial cells in lumbar spinal 
cord at 6 months after subpial AAV9-UBI-RFP delivery in rats. (a–i) Confocal 
analysis of GFP-expressing cells in the lumbar spinal cord at 6 months after 
subpial AAV9-UBI-GFP delivery in rats shows consistently labeled astrocytes 
(a–c; white arrows), oligodendrocytes (d–f; white arrows) and endothelial 
cells (g–i; white arrows) (Scale bars: a, d, g-30 μm).
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synapse formation between labeled motor axons of the host and spi-
nally grafted cells. Such data systematically characterizing the level 
of axonal sprouting and/or the development of synaptic contacts 
in cell-grafted large animal models of spinal injury are currently not 
available.
Pros and cons of using subpial gene delivery technique
As described, the primary advantage of SP AAV9 delivery, if com-
pared to intrathecal delivery, appears to be superior spinal trans-
parenchymal transgene expression. In addition, a comparable 
high-level of transgene expression is achieved in both adult rats 
and minipigs. Because the dimension of the spinal cord in adult 
35–40 kg pigs is similar to humans, it is expected that a similar 
parenchymal AAV9 uptake will also be achieved in adult humans.
One of the limitations of the SP delivery technique is the require-
ment to perform local laminectomy to gain access to the dorsal sur-
face of the SP-injected spinal cord. The requirement for laminectomy 
can limit its repetitive use, compared to intrathecal delivery, which 
can be used repetitively. However, the degree of transgene expres-
sion that can be achieved after SP AAV9 delivery appears to balance, 
if not surpass, this limitation should a clear and more potent thera-
peutic effect be seen once SP-based gene delivery is used in disease 
modifying studies. In addition, we have recently observed a sustained 
high-level of spinal GFP expression at 12 months in the lumbar spinal 
cord in naive-control rats and pigs receiving AAV9-UBI-GFP (unpub-
lished observation). This would indicate that a single SP delivery of a 
therapeutic gene could potentially lead to a long-lasting effect before 
additional gene delivery needs to be considered.
Recent studies using nonhuman primates have demon-
strated a substantial pathology and inflammatory changes in 
the cerebellum after intracisternal delivery of AAV9-encoding 
GFP (a non-self protein derived from jellyfish). Importantly, in the 
same study it was demonstrated that the expression of human 
aromatic L-amino acid decarboxylase (hAADC), a self-protein, 
has minimal proinflammatory and neurodegenerative effects.11 
While the degree of inflammatory changes caused by GFP or RFP 
expression was not specifically addressed in our current study, the 
behavioral data show normal neurological (motor and sensory) 
function in rats and pigs at chronic stages (up to 6 months) after 
subpial AAV9-UBI-GFP delivery. These data would suggest that 
even if inflammatory changes were present, these do not have 
a major neurological function-deterioration effect. Nonetheless, 
as demonstrated in previous nonhuman primate study,11 careful 
consideration needs to be paid into the design of control-reporter 
or combined reporter-treatment AAV9 vectors to be used in the 
preclinical safety as well as efficacy studies.
Conclusion
Using adult rats and pigs, we have developed a novel subpial spinal 
cord AAV9 delivery technique that permits widespread transgene 
expression in the spinal parenchyma, descending and ascending 
axons, and does not require direct spinal cord tissue needle penetra-
tion (see summary diagram, Figure 9). In addition to spinal regional 
transgene expression, robust retrograde expression in brain motor 
centers was seen. This technique can potentially be used in preclini-
cal studies and human clinical trials designed to upregulate or down-
regulate a gene of interest in specific spinal cord segments and/or in 
projecting motor and ascending sensory axons. The simplicity of this 
approach and potency of transgene expression in adult animals sug-
gest that this technique may be successfully used in the adult patient 
Figure 9 Schematic diagram demonstrating the technique of subpial AAV9 delivery and resulting transgene (GFP) expression throughout the CNS 
after a single subpial AAV9-UBI-GFP injection. The AAV9-UBI-GFP virus is delivered into the subpial space using a PE-10 catheter in adult pigs. Subpial 
delivery of AAV9-UBI-GFP leads to diffusion and resulting uptake of virus into segmental neurons (interneurons and α-motoneurons) and ascending 
and descending axons that are trans-passing through the SP-injected segments. Resulting transgene expression is then seen in: (i) segmental neurons, 
(ii) dorsal root ganglion cells (retrograde infection), (iii) motor axons innervating skeletal muscles (anterograde infection), (iv) pyramidal neurons in 
motor cortex (retrograde infection), and (v) brain terminals of spinothalamic neurons (anterograde infection).
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population and can target a variety of spinal neurological disorders, 
including ALS, spinal trauma or chronic pain syndrome.
MATeRIAlS AND MeTHODS
Animals and general surgical preparation
These studies were carried out under protocols approved by the Institutional 
Animal Care and Use Committee of the Czech Academy of Sciences and by the 
Institutional Animal Care and Use Committees of the University of California, 
San Diego and were in compliance with The Association for Assessment of 
Laboratory Animal Care guidelines for animal use. All studies were performed 
in such a manner as to minimize group size and animal suffering.
Adult Sprague-Dawley rats (male and female, 250–350 g; n = 19; see Table 1 
for experimental Groups) or adult minipigs resulting from cross-breeding of 
Minnesota and Gottingen strains (both sexes; 30–40 kg; n = 8; Table  1) were 
used. Rats were anesthetized with 5% isoflurane and maintained at 2–3% isoflu-
rane during surgery depending on breathing rate and paw pinch response. The 
back of the rat was then shaved and cleaned with 2% chlorhexidine. After skin 
incision, the paravertebral muscle surrounding the cervical, thoracic or lumbar 
spinal vertebrae was removed, and animals were mounted into a spinal immo-
bilization frame (Stoelting) using Cunningham’s spinal clamps, as previously 
described.12 To expose the spinal cord, a dorsal laminectomy of corresponding 
vertebra was performed using a dental drill. The dura was then cut open using a 
scalpel blade or 30G needle.
Minipigs were premedicated with intramuscular azaperonum (2 mg/kg) 
and atropine (1 mg/kg; Biotika, SK) and then induced with ketamine (20 mg/
kg; i.v.). After induction, animals were intubated with a 2.5F tracheal tube. 
Anesthesia was maintained with 1.5% isoflurane in 50%/50% air/oxygen 
mixture at a constant 2 l/minute flow rate. Oxygen saturation was monitored 
throughout the procedure using a pulse oximeter (Nellcor Puritan Bennett, 
Ireland). After induction of anesthesia, animals were placed into a spinal 
immobilization apparatus, as described previously.13 A dorsal laminectomy 
of Th5 or L2-L4 vertebrae, corresponding to Th5 and L3-L6 spinal segments, 
respectively, was then performed, and epidural fat removed using cotton 
swabs. The dura was cut open and secured to the surrounding tissue using 
6.0 Proline (Figure 1c–e).
Placement of subpial catheter and subpial AAV9 injection
To place the subpial catheter, an L-shaped catheter guiding tube (18 or 23G) 
was constructed (Figure  1b). The guiding tube was mounted into an XYZ 
(Stoelting) manipulator and advanced to the surface of the exposed spinal 
segment. A 30G needle, previously bent at a 45° angle, was used to punc-
ture the pia. The subpial catheter (PE-10 for pigs and PE-5 for rats) was then 
advanced into the subpial space from the guiding tube by manually pushing 
the catheter from the other end of the guiding tube. In rats, the catheter was 
advanced into the subpial space for about 1–1.5 cm and in pigs for about 
3–6 cm. The virus was then injected into the SP space over 3 minutes using 
a 50 or 250 μl Hamilton syringe. After injection, the catheter was removed, 
dura closed using 6.0 Proline (in pigs only), and animals allowed to recover.
Placement of lumbar intrathecal catheter in rats
In some rats a lumbar intrathecal PE-5 catheter was placed. Under isoflurane 
anesthesia, an 8.5 cm PE-5 catheter (Spectranetics, Colorado Springs, CO) con-
nected to 5 cm of polyethylene-PE-10 tube was inserted through an incision 
in the atlanto-occipital membrane of the cisterna magna.14 The PE-10 catheter 
end was then externalized behind the head. Ten minutes after intrathecal AAV9 
injection, the catheter was removed and the skin incision closed with 3.0 silk.
Preparation of AAV9 for in vivo injection
The 1.2 kb ubiquitin-C (UBC) promoter was made by oligonucleotide syn-
thesis, linked with either eGFP or DsRed (RFP) and SV40 polyA signal, and 
cloned into a self-complementary double-strand DNA genome AAV (scAAV) 
vector plasmid.15 Helper virus-free scAAV9 vectors expressing either eGFP 
or RFP driven by UBC promoter were produced by transient transfection 
of HEK293T cells with the vector plasmid pRep2-Cap9 and pAd-helper 
plasmids.16 Plasmid pRep2-Cap9 was obtained from the Vector Core at 
the University of Pennsylvania. AAV vectors in the cell lysates prepared at 
72 hours after transfection were purified as previously described and titered 
by Q-PCR.15 The final titers were adjusted to 1.0x10^13 genome copies per 
ml (gc/ml). Just before injection, the virus was mixed with dextran (10,000 
MW) 1:1 to a final dextran concentration of 2.5%. The volume of subpial 
injectate was 30 μl in rats and 200 μl in pigs.
Perfusion fixation, postmortem in situ GFP fluorescence imaging, 
and immunofluorescence staining of spinal cord and brain sections
At 2–6 months after AAV9 delivery animals (rats and pigs; see Table 1) were 
deeply anesthetized with pentobarbital and transcardially perfused with 
200 ml (rats) or 2,000 ml (pigs) of heparinized saline followed by 250 ml 
(rats) or 4,000 ml (pigs) of 4% paraformaldehyde in phosphate-buffered 
saline (PBS). The spinal cords and brains were dissected and post-fixed in 
4% formaldehyde in PBS overnight at 4 °C. After postfixation, the whole 
spinal cord(s) was imaged in situ using Spectrum optical imaging system 
(Xenogen, Alameda, CA). Sequences were acquired at excitation wave-
length 465 nm and emission wavelength 520 nm. Medium binning was 
used, and the exposure time was 3 seconds. Images were analyzed using 
Living Image 4.3.1 (Xenogen, Alameda, CA) software. The signals were 
calculated using fixed volume region of interests (ROIs). Spinal cords 
were then cryoprotected in 30% sucrose PBS until transverse or longi-
tudinal sections (30-μm-thick) were cut on a cryostat and stored in PBS.
Prepared sections were immunostained overnight at 4°C with the follow-
ing primary antibodies made in PBS with 0.2% Triton X-100: rabbit anti-GFAP 
(1:500, Origene, Rockville, MD), mouse anti-neuronal nuclei antigen (NeuN, 
1:1,000, Chemicon, Temecula, CA), mouse anti-oligodendrocyte (adenoma-
tosis polyposis coli (APC) (CC1); 1:500; Millipore), mouse anti-endothelial 
(RECA-1; 1: 1,000; Abcam, Cambridge, MA). No anti-GFP or anti-RFP antibody 
was used.
After incubation with primary antibodies, sections were washed three 
times in PBS and incubated with fluorescent-conjugated secondary 
Table 1 Experimental groups
Animal model Adult SD rat Adult minipig
Segmental level Cervical Thoracic Lumbar Cervical Thoracic Lumbar
Intrathecal AAV9 – – N = 5 (&) – – –
Subpial AAV9 N = 4*; 
 N = 4* (&)
– N = 6 (#) – N = 4 (&) N = 4 (#)
*-AAV9-UBI-GFP; *-AAV9-UBI-RFP; (#)-6 months survival; (&) – 6–8 weeks 
months survival.
Table 2 Quantification (%) of GFP expressing NeuN+ interneurons and α-motoneurons at 6 months after lumbar (L2) subpial AAV9-UBI 
delivery in SD rat and minipig
Segment(s) Neuron type Th10 Th11 Th12 L1 L2 L3 L4 L5 L6 S1
SD rat (n = 3) α-moto 78 ± 9 87 ± 11 90 ± 6 89 ± 6 95 ± 4 94 ± 6 93 ± 5 88 ± 6 99 ± 3 91 ± 8
Intern. 96 ± 4 93 ± 5 96 ± 7 98 ± 6 97 ± 2 92 ± 3 81 ± 9 72 ± 9 77 ± 11 90 ± 6
Minipig (n = 3) α-moto 56 ± 14 54 ± 8 76 ± 12 94 ± 2 92 ± 6 94 ± 7 78 ± 9 56 ± 14 49 ± 16 50 ± 11
Intern. 90 ± 11 90 ± 7 89 ± 4 96 ± 4 98 ± 2 90 ± 7 83 ± 11 76 ± 16 80 ± 12 82 ± 16
α-moto-α-motoneurons; Intern.- interneurons.
10
Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs
A Miyanohara et al.
Molecular Therapy — Methods & Clinical Development (2016) 16046 Official journal of the American Society of Gene & Cell Therapy
donkey anti-rabbit and donkey anti-mouse antibodies (Alexa Fluor 488, 
546 or 647, 1:1,000, Invitrogen, Waltham, MA), respectively, and DAPI for 
general nuclear staining. In sections expressing AAV9-UBI-induced GFP, 
Alexa Fluor 594 or 647 was used, while Alexa 488 or 647 was employed as 
secondary antibody in sections expressing AAV9-UBI-induced RFP.
Sections were then mounted on slides, dried at room temperature and 
covered with a Prolong anti-fade kit (Invitrogen). Fluorescence images were 
captured using a Zeiss Imager M2 microscope and confocal images were 
taken using an Olympus FV1000 microscope.
Quantitative analysis and densitometry measurement of neuronal 
AAV9-UBI-induced GFP expression
To determine the threshold of AAV9-induced GFP expression, densitom-
etry analysis of GFP signal was performed and compared to naive con-
trols. Images were captured from serially cut transverse sections taken 
from above, at the center and below the level of subpial AAV9 injection 
as well as from naive-noninjected animals. All sections were stained with 
NeuN antibody. Because of the very high intensity of AAV9-induced GFP 
signal, no anti-GFP staining was used. Mosaic images (tile scan) captured 
from selected sections using identical lamp and exposure time intensity 
(the lamp is set to 50% and the exposure time is 5 ms) were then collected. 
The intensity of GFP signal in neuronal bodies was then compared to naive 
controls and the threshold that identified GFP positive neurons deter-
mined using signal densitometry (Supplementary Figure S2). Percentage 
of GFP positive NeuN+ neurons (interneurons, α-motoneurons) was then 
estimated and quantified in individual segments respective to the seg-
ment of subpial AAV9 delivery. For quantification, rats (n = 3) and pigs (n 
= 3) previously injected with L2 subpial AAV9-UBI-GFP and surviving for 6 
months were used (Table 2). Three sections taken from each segment of 
each animal were used for quantification.
Analysis of motor and sensory function
The long-term (6 months’ survival) effect of lumbar subpial AAV9-UBI-GFP 
delivery on neurological function was analyzed in six rats and four pigs in 
7-day intervals.
Open-field locomotion testing in rats. Changes in motor function in the rat 
was assessed using a Basso, Beattie, Bresnahan open-field 21 grade locomo-
tion rating scale.17
Analysis of motor function in pigs. The previously developed 14 grade por-
cine motor scoring system was used.18 In both models, the presence of al-
lodynia was tested by presence/absence of vocalization/withdrawal from 
touching the trunk below the level of subpial AAV9 delivery with a 20 g von 
Frey filament (rats) or by skin pinch (pigs).
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